ODAC recommends new indication for Femara

Novartis (NVS; SWX:NOVN) said that the Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of Femara (letrozole), an oral aromatase inhibitor, by as a first line treatment of ad...